Table 4 Outcomes and cost of care per patient (discounted 25-year data)

From: Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial

 

Outcomes

Cost (£)

Treatment

QALYs (years)

LYG (years)

Drug

Adverse events

Follow-up

Recurrence and palliative care

Total

Anastrozole

9.206

9.464

3598

1347

2735

2254

9935

Tamoxifen

8.962

9.234

113

1366

1539

2603

5620

  1. Abbreviations: LYG=life-years gained; QALYs=quality-adjusted life-years gained.
Back to article page